Alnylam Pharmaceuticals Stock News

Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet

Several Street firms are maintaining bullish views on Alnylam Pharmaceuticals following the biotech Q4 2021 earnings results Thursday.

Alnylam's (ALNY) earnings fall shy of estimates in the fourth quarter of 2021 while revenues beat the same. The company issues 2022 guidance for net product revenues.

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ: ALNY ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 2 0 0 Last 30D 0 0 1 0 0 1M Ago 2 1 1 0 0 2M Ago 0 1 0 0 0 3M Ago 2 1 0 0 0 In the last 3 months, 9 analysts have offered 12-month price targets for Alnylam Pharmaceuticals. The company has an average price target of $206.44 with a high of $350.00 and a low of $103.00. Below is a summary of how these 9 analysts rated Alnylam Pharmaceuticals over the past … Full story available on Benzinga.com

CharlieAJA/iStock via Getty Images Alnylam Pharmaceuticals (ALNY +3.0%) is trading higher after the company reported better than expected revenue for Q4 2021, while the bottom line missed…

Alnylam Pharmaceuticals Inc''s (NASDAQ: ALNY ) Q4 product revenues increased 76% Y/Y to $198.5 million , primarily due to the continued global expansion of Onpattro and Givlaari, and sales from a third commercial product, Oxlumo. Collaborations sales increased 18%, primarily due to increased revenue from collaboration agreements with Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) and Novartis AG (NYSE: Full story available on Benzinga.com

Alnylam Pharmaceuticals press release (ALNY): Q4 Non-GAAP EPS of -$1.69 misses by $0.43.Revenue of $258.54M (+58.1% Y/Y) beats by $24.92M.Shares +0.2% PM.Provides 2022 Combined…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2021 and reviewed recent business highlights. 2021 was another remarkable year at Alnylam, in which we delivered significant product revenue growth of 83% compared to 2020, achieving results at the upper end of our combined product sales guidance range driven by strong pa

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.

Alnylam Pharmaceuticals' (ALNY) CEO Yvonne Greenstreet on Q4 2021 Results - Earnings Call Transcript

Alnylam Pharmaceuticals Inc's  ALNY Q4 product revenues increased 76% Y/Y to $198.5 million, primarily due to the continued global expansion of Onpattro and Givlaari, and sales from a third commerci

Alnylam (ALNY) delivered earnings and revenue surprises of -46.94% and 8.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to announce Q4 earnings results on Thursday, February 10th, before market open.The consensus EPS Estimate is -$1.26 (+21.3% Y/Y) and…